<DOC>
	<DOCNO>NCT03059277</DOCNO>
	<brief_summary>The purpose study determine efficacy intravitreal aflibercept injection administer treat extend fashion eye persistent center involve diabetic macular edema follow least 4 intravitreal injection 0.3 mg ranibizumab 24 week .</brief_summary>
	<brief_title>Intravitreal Alfibercept Center Involved DME Previously Managed With Intravitreal Ranibizumab</brief_title>
	<detailed_description>This phase 4 prospective , nonrandomized , open label , interventional clinical trial determine efficacy intravitreal aflibercept ( IAI ) administer treat extend fashion eye persistent center involved diabetic macular edema despite least 4 intravitreal injection ranibizumab 0.3mg 24 week prior enrollment . Patients receive intravitreal injection aflibercept ( 2mg/0.05cc ) baseline monthly eye reach stability define : &lt; 10 % change Spectral Domain Optical Coherence Tomography ( SD OCT ) central retinal thickness ( CRT ) read previous 2 visit ( include baseline ) less 5 letter decrease Best Corrected Visual Acuity ( BCVA ) best BCVA prior visit . Once eye reach stability criterion , treat extend protocol use treatment render every visit . The duration treatment extend 2 week last visit SD OCT extension criterion meet : &lt; 10 % change CRT 2 consecutive visit &lt; 5 letter decrease BCVA baseline If return visit subretinal and/or intraretinal fluid recurs cause CRT increase &gt; 10 % low level previous 2 consecutive visit , CRT increase &lt; 10 % due subretinal and/or intraretinal fluid associate decrease BCVA &gt; 5 letter baseline eye receive IAI treatment interval decrease 1 week . If eye improve worsen least 2 consecutive visit SD OCT central subfield thickness ≥ 300 micron visual acuity bad 20/20 , follow do : Prior 24-week visit , injection give . At 24-week visit , injection give modify grid laser give discretion investigator within 7 day IAI base rescue criterion</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥18 year type 1 type 2 diabetes Best Corrected Visual Acuity ( ETDRS ) letter score study eye ≤ 85 ≥24 ( approximate Snellen equivalent 20/20 20/320 ) Central retinal thickness SD OCT baseline visit &gt; 300 micron use Heidelberg Spectralis definite evidence intraretinal subretinal fluid due diabetic retinopathy CSF . Patients must receive least four intravitreal ranibizumab 0.3 mg injection within 24 week prior screen fail complete resolution intraretinal subretinal fluid SD OCT CRT &gt; 300 micron use Heidelberg Spectralis Laser photocoagulation ( panretinal macular ) study within 90 day baseline Active high risk proliferative diabetic retinopathy ( PDR ) History intravitreal corticosteroid within 4 month baseline History intravitreal bevacizumab within 24 week baseline History idiopathic autoimmune uveitis study eye Cataract surgery study eye within 90 day baseline Any intraocular surgery within 90 day baseline Vitreomacular traction epiretinal membrane study eye think affect vision Evidence active infection either eye Uncontrolled glaucoma study eye define pressure &gt; 25 mmHg maximal medical therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetes</keyword>
	<keyword>reduce treatment frequency</keyword>
</DOC>